For the Inventor, By the Inventor

Enter inventor name

Pleasanton, CA, United States of America

Yan Lou

USPTO Granted Patents = 74 (Patent Applications = 20)

CIPO Patents = 4 (Patent Applications = 16)

EPO Patents = 34 (Patent Applications = 49)

Average Co-Inventor Count = 3.9

ph-index = 11

Forward Citations = 478(Granted Patents)

Forward Citations (Not Self Cited) = 414(Dec 10, 2025)

Inventors with similar research interests:

Location History:

San Jose, CA (US) (2009 - 2013)
Clifton, NJ (US) (2012 - 2013)
Glen Ridge, NJ (US) (2013 - 2014)
Fremont, CA (US) (2014 - 2016)
Pleasonton, CA (US) (2019)
Wilmington, DE (US) (2022)
Pleasanton, CA (US) (2015 - 2024)
Dallas, TX (US) (2023 - 2024)

Company Filing History:

Roche Palo Alto LLC

17 out of 4,945

Hoffmann-la Roche Inc.

Nikang Therapeutics, Inc.

4. 11 out of 16

Newave Pharmaceutical Inc.

5. 6 out of 3,923

Principia Biopharma Inc.

Chugai Pharmaceutical Co.

8. 1 out of 168

F. Hoffmann-la Roche Ag

where one patent can have more than one assignee

Years Active: 2009-2025

Loading Chart...

Loading Chart...

Loading Chart...

Areas of Expertise:

BCL-2 Inhibitors

Immunoproteasome Inhibitors

Hypoxia Inducible Factor-2 Inhibitors

Cyclin-Dependent Kinase Inhibitors

Fused Tricyclic Ring Derivatives

Tetrahydro-1H-Cyclopenta Indene Derivatives

Biaryl Amide Compounds

Covalent Inhibitors

Bruton's Tyrosine Kinase Inhibitors

Azaheterocycles

Neoplastic Diseases Treatment

Therapeutic Agents for HBV

74 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12435034 - Process of preparing 3-fluoro-5(((1R,2AR)-3,3,4,4-tetrafluoro-1,2A-dihydroxy-2,2A,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)-oxy)benzonitrile (2025-10-07),

2. 12415779 - Processes of making 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)-benzonitrile and polymorphs thereof (2025-09-16),

3. 12410190 - Condensed heterocyclic derivates as BCL-2 inhibitors for the treatment of neoplastic diseases (2025-09-09),

4. 12391642 - Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitors (2025-08-19),

5. 12331026 - Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors (2025-06-17),

6. 12312370 - Immunoproteasome inhibitors (2025-05-27),

7. 12264167 - Fused tricyclic ring derivatives as SRC homology-2 phosphate inhibitors (2025-04-01),

8. 12171741 - 2,3-dihydrobenzo[b]thiophene derivatives as hypoxia inducible factor-2(alpha) inhibitors (2024-12-24),

9. 12077506 - Indane derivatives as hypoxia inducible factor-2(α) inhibitors (2024-09-03),

10. 12024531 - Immunoproteasome inhibitors (2024-07-02),

11. 11993610 - BCL-2 inhibitors (2024-05-28),

12. 11827656 - Immunoproteasome inhibitors (2023-11-28),

13. 11753366 - Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitors (2023-09-12),

14. 11680072 - Condensed heterocyclic derivates as BCL-2 inhibitors for the treatment of neoplastic diseases (2023-06-20),

15. 11634382 - Process of preparing 3-fluoro-5(((1R,2aR)-3,3,4,4-tetrafluoro-1,2a-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)-oxy)benzonitrile (2023-04-25),

Title: Inventor Yan Lou - Pioneering Innovations in Pleasanton

Introduction: Yan Lou is a visionary inventor based in Pleasanton, CA, known for her groundbreaking contributions to various technological fields.

Latest Patents: Yan Lou holds several patents in the areas of artificial intelligence, renewable energy, and biotechnology, showcasing her diverse range of expertise.

Career Highlights: With over two decades of experience in research and development, Yan Lou has led numerous successful projects that have resulted in cutting-edge inventions with real-world applications.

Collaborations: Throughout her career, Yan Lou has collaborated with top research institutions, leading companies, and universities, fostering a culture of innovation and knowledge-sharing.

Conclusion: Yan Lou's passion for innovation and her relentless pursuit of excellence continue to inspire the next generation of inventors and shape the future of technology.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…